Literature DB >> 25613376

TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation.

M T Epping1, A Lunardi1, D Nachmani1, M Castillo-Martin2, T H Thin2, C Cordon-Cardo2, P P Pandolfi1.   

Abstract

REST/NRSF is a transcriptional repressor of neuronal genes that has been implicated in development and cancer. In epithelial tissues, REST acts as a tumor suppressor and in breast cancer, loss of REST is associated with disease recurrence and poor prognosis. Here, we identify TSPYL2 (also known as CDA1 and DENTT) as a novel component of the REST protein complex. We show that REST and TSPYL2 are regulators of TGFβ signaling and that cell-cycle arrest induced by TGFβ requires both REST and TSPYL2. Importantly, knockdown of REST or TSPYL2 resulted in transformation of human mammary epithelial cells. Mechanistically, we demonstrate that the TSPYL2/REST complex promotes TGFβ signaling by repressing the expression of genes, such as the proto-oncogene neurotrophic tyrosine kinase receptor C (TrkC). These data provide insight into the role of REST as a tumor suppressor in epithelial tissues through the regulation of the TGFβ pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25613376      PMCID: PMC4495358          DOI: 10.1038/cdd.2014.226

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  40 in total

1.  A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.

Authors:  S R Knezevich; D E McFadden; W Tao; J F Lim; P H Sorensen
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

Review 2.  REST in good times and bad: roles in tumor suppressor and oncogenic activities.

Authors:  Sadhan Majumder
Journal:  Cell Cycle       Date:  2006-09-01       Impact factor: 4.534

3.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

Authors:  Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

4.  Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways.

Authors:  Yugang Tu; Weiping Wu; Tieqiao Wu; Zemin Cao; Richard Wilkins; Ban-Hock Toh; Mark E Cooper; Zhonglin Chai
Journal:  J Biol Chem       Date:  2007-02-22       Impact factor: 5.157

5.  Differentially expressed nucleolar transforming growth factor-beta1 target (DENTT) exhibits an inhibitory role on tumorigenesis.

Authors:  Lana E Kandalaft; Enrique Zudaire; Sergio Portal-Núñez; Frank Cuttitta; Sonia B Jakowlew
Journal:  Carcinogenesis       Date:  2008-04-01       Impact factor: 4.944

6.  Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis.

Authors:  Y Pham; Y Tu; T Wu; T J Allen; A C Calkin; A M Watson; J Li; K A Jandeleit-Dahm; B-H Toh; Z Cao; M E Cooper; Z Chai
Journal:  Diabetologia       Date:  2009-10-22       Impact factor: 10.122

7.  ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.

Authors:  Zhe Li; Cristina E Tognon; Frank J Godinho; Laura Yasaitis; Hanno Hock; Jason I Herschkowitz; Chris L Lannon; Eunah Cho; Seong-Jin Kim; Roderick T Bronson; Charles M Perou; Poul H Sorensen; Stuart H Orkin
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

8.  Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity.

Authors:  Roderik M Kortlever; Jeroen H Nijwening; René Bernards
Journal:  J Biol Chem       Date:  2008-07-09       Impact factor: 5.157

9.  CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation.

Authors:  Peter Mulligan; Thomas F Westbrook; Matthias Ottinger; Natalya Pavlova; Bin Chang; Eric Macia; Yu-Jiang Shi; Jordi Barretina; Jinsong Liu; Peter M Howley; Stephen J Elledge; Yang Shi
Journal:  Mol Cell       Date:  2008-12-05       Impact factor: 17.970

10.  TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling.

Authors:  W Jin; C Yun; M-K Kwak; T-A Kim; S-J Kim
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

View more
  15 in total

1.  TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage.

Authors:  Martina Magni; Giacomo Buscemi; Lucia Maita; Lei Peng; Siu Yuen Chan; Alessandra Montecucco; Domenico Delia; Laura Zannini
Journal:  Cell Death Differ       Date:  2018-07-26       Impact factor: 15.828

2.  The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants.

Authors:  Yunmin Li; Dong Ji Zhang; Yun Qiu; Tatsuo Kido; Yun-Fai Chris Lau
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

3.  REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.

Authors:  Anantha L Marisetty; Li Lu; Bethany L Veo; Bin Liu; Cristian Coarfa; Mohamed Mostafa Kamal; Dina Hamada Kassem; Khushboo Irshad; Yungang Lu; Joy Gumin; Verlene Henry; Adriana Paulucci-Holthauzen; Ganesh Rao; Veerabhadran Baladandayuthapani; Frederick F Lang; Gregory N Fuller; Sadhan Majumder
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

4.  Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.

Authors:  Melody Abikhair Burgo; Nazanin Roudiani; Jie Chen; Alexis L Santana; Nicole Doudican; Charlotte Proby; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2018-09-06

5.  Transcriptional Basis for Rhythmic Control of Hunger and Metabolism within the AgRP Neuron.

Authors:  Jonathan Cedernaes; Wenyu Huang; Kathryn Moynihan Ramsey; Nathan Waldeck; Lei Cheng; Biliana Marcheva; Chiaki Omura; Yumiko Kobayashi; Clara Bien Peek; Daniel C Levine; Ravindra Dhir; Raj Awatramani; Christopher A Bradfield; Xiaozhong A Wang; Joseph S Takahashi; Mohamad Mokadem; Rexford S Ahima; Joseph Bass
Journal:  Cell Metab       Date:  2019-02-28       Impact factor: 27.287

6.  MiR-30e-5p and MiR-15a-5p Expressions in Plasma and Urine of Type 1 Diabetic Patients With Diabetic Kidney Disease.

Authors:  Cristine Dieter; Taís Silveira Assmann; Aline Rodrigues Costa; Luís Henrique Canani; Bianca Marmontel de Souza; Andrea Carla Bauer; Daisy Crispim
Journal:  Front Genet       Date:  2019-06-12       Impact factor: 4.599

7.  The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner.

Authors:  Tatsuo Kido; Yunmin Li; Yuichiro Tanaka; Rajvir Dahiya; Yun-Fai Chris Lau
Journal:  Oncotarget       Date:  2019-02-19

Review 8.  Battle of the sexes: contrasting roles of testis-specific protein Y-encoded (TSPY) and TSPX in human oncogenesis.

Authors:  Yun-Fai Chris Lau; Yunmin Li; Tatsuo Kido
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

9.  TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Sisi Qin; Duan Liu; Manish Kohli; Liguo Wang; Peter T Vedell; David W Hillman; Nifang Niu; Jia Yu; Richard M Weinshilboum; Liewei Wang
Journal:  Clin Pharmacol Ther       Date:  2017-11-22       Impact factor: 6.875

10.  Transcriptional downregulation of miR-133b by REST promotes prostate cancer metastasis to bone via activating TGF-β signaling.

Authors:  Shuai Huang; Qingde Wa; Jincheng Pan; Xinsheng Peng; Dong Ren; Qiji Li; Yuhu Dai; Qing Yang; Yan Huang; Xin Zhang; Wei Zhou; Dan Yuan; Jiazheng Cao; Yuming Li; Peiheng He; Yubo Tang
Journal:  Cell Death Dis       Date:  2018-07-13       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.